JP2019194236A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194236A5
JP2019194236A5 JP2019127476A JP2019127476A JP2019194236A5 JP 2019194236 A5 JP2019194236 A5 JP 2019194236A5 JP 2019127476 A JP2019127476 A JP 2019127476A JP 2019127476 A JP2019127476 A JP 2019127476A JP 2019194236 A5 JP2019194236 A5 JP 2019194236A5
Authority
JP
Japan
Prior art keywords
compound
salt
compound according
group
compound selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019127476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019194236A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194236A publication Critical patent/JP2019194236A/ja
Publication of JP2019194236A5 publication Critical patent/JP2019194236A5/ja
Priority to JP2022041396A priority Critical patent/JP7375072B2/ja
Pending legal-status Critical Current

Links

JP2019127476A 2014-09-17 2019-07-09 Mk2阻害剤およびその使用 Pending JP2019194236A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022041396A JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017515845A Division JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022041396A Division JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Publications (2)

Publication Number Publication Date
JP2019194236A JP2019194236A (ja) 2019-11-07
JP2019194236A5 true JP2019194236A5 (pt-PT) 2019-12-19

Family

ID=55454109

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用
JP2019127476A Pending JP2019194236A (ja) 2014-09-17 2019-07-09 Mk2阻害剤およびその使用
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Mk2阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Mk2阻害剤およびその使用

Country Status (30)

Country Link
US (5) US9458175B2 (pt-PT)
EP (2) EP3193611B1 (pt-PT)
JP (3) JP6556225B2 (pt-PT)
KR (1) KR102457848B1 (pt-PT)
CN (1) CN106998692B (pt-PT)
AU (1) AU2015317741B2 (pt-PT)
BR (1) BR112017005266B1 (pt-PT)
CA (1) CA2961607C (pt-PT)
CL (1) CL2017000576A1 (pt-PT)
CO (1) CO2017003279A2 (pt-PT)
CY (1) CY1124215T1 (pt-PT)
DK (1) DK3193611T3 (pt-PT)
EA (1) EA037299B1 (pt-PT)
EC (1) ECSP17023281A (pt-PT)
ES (1) ES2874561T3 (pt-PT)
HR (1) HRP20210529T1 (pt-PT)
HU (1) HUE054347T2 (pt-PT)
IL (1) IL251051B (pt-PT)
LT (1) LT3193611T (pt-PT)
MA (1) MA40534B1 (pt-PT)
MX (2) MX2017003359A (pt-PT)
NZ (1) NZ730603A (pt-PT)
PL (1) PL3193611T3 (pt-PT)
PT (1) PT3193611T (pt-PT)
RS (1) RS62017B1 (pt-PT)
SA (1) SA517381115B1 (pt-PT)
SG (2) SG11201701861RA (pt-PT)
SI (1) SI3193611T1 (pt-PT)
TW (1) TWI744217B (pt-PT)
WO (1) WO2016044463A2 (pt-PT)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163738A (zh) 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
EP3193611B1 (en) 2014-09-17 2021-03-24 Celgene Car Llc Mk2 inhibitors and uses thereof
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
MX2019010643A (es) * 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
KR20220041042A (ko) * 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
WO2021163633A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
JP2023536427A (ja) * 2020-07-24 2023-08-25 ブリストル-マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
RU2005119173A (ru) 2002-12-20 2006-02-27 Фармация Корпорейшн (Us) Ациклические пиразольные соединения
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス, インコーポレイテッド c−Kit調節因子および使用方法
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2008277676A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as MK2 inhibitors
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2817388B1 (en) 2012-02-22 2020-03-25 Merck Patent GmbH Liquid crystalline medium
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
SG11201502184VA (en) * 2012-09-24 2015-04-29 Claremont Speede Mobile sender controlled data access and data deletion method and system
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Gsk3阻害剤と抗dr5抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
EP3193611B1 (en) 2014-09-17 2021-03-24 Celgene Car Llc Mk2 inhibitors and uses thereof
RU2017128077A (ru) 2015-01-08 2019-02-08 Мори Матрикс, Инк. Составы, содержащие пептиды, ингибирующие мк2
MX2019010643A (es) 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
KR20220041042A (ko) 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル-マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法

Similar Documents

Publication Publication Date Title
JP2019194236A5 (pt-PT)
JP2018024670A5 (pt-PT)
JP2020515557A5 (pt-PT)
JP2021020948A5 (pt-PT)
JP2022078315A5 (pt-PT)
JP2018168171A5 (pt-PT)
JP2019089762A5 (pt-PT)
JP2018150298A5 (pt-PT)
JP2018521020A5 (pt-PT)
JP2009149903A5 (pt-PT)
JP2017222697A5 (pt-PT)
JP2018536572A5 (pt-PT)
JP2013532130A5 (pt-PT)
JP2016153424A5 (pt-PT)
JP2011518833A5 (pt-PT)
JP2009535462A5 (pt-PT)
JP2010501534A5 (pt-PT)
JP2011527560A5 (pt-PT)
JP2012111758A5 (pt-PT)
JP2011105738A5 (pt-PT)
EP4335439A3 (en) Compounds
JP2014221779A5 (pt-PT)
JP2016520672A5 (pt-PT)
JP2015199738A5 (pt-PT)
JP2014235432A5 (pt-PT)